Driven to help people live better lives

Through strong science and careful clinical evaluation, we aim to develop microbiota-based live biotherapeutics that bring the potential of the human microbiome to the patients and physicians who need them most.

In 2018, Rebiotix joined Ferring Pharmaceuticals, a globally-recognized specialty pharmaceutical company driven to help people live better lives. Combined with their history and passion for microbiome-based research, our ability to make microbiota-based live biotherapeutics may soon be a reality.

The Leader in Developing Microbiota-Based Therapies through the MRT™ Drug Platform

The MRT platform is our technology for developing formulations consisting of live, human-derived microbes.

We have the most advanced human clinical program with extensive clinical trial experience in multiple indications, evaluating an investigative microbiota-based live biotherapeutic drug. Our research, conducted in coordination with regulatory authorities, encompasses studies with acute and chronic disease states through both company- and physician-sponsored trials. Check out our clinical program, including our advanced investigative programs for recurrent Clostridioides difficile infection, for more information.

Rebiotix Inc., a Ferring Company news

Contact supplier